Given that toremifene is primarily used in postmenopausal women as opposed to tamoxifen whose use is recommended in both pre- and post-menopausal women with ER/PR positive breast cancer [11], toremifene users tend to be older than tamoxifen users, which may have played a role in differential outcomes per SERM agent. Here, ESR1 is linked to breast carcinoma.